Current status and problems in the diagnosis and treatment of premenstrual syndrome and premenstrual dysphoric disorder from the perspective of obstetricians and gynecologists in Japan.
diagnostic criteria
oral contraceptive pills
premenstrual dysphoric disorder
premenstrual syndrome
selective serotonin reuptake inhibitors
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
06
10
2022
accepted:
06
02
2023
medline:
3
5
2023
pubmed:
24
2
2023
entrez:
23
2
2023
Statut:
ppublish
Résumé
To investigate the current status and problems in the diagnosis and treatment of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) from the perspective of obstetricians and gynecologists (OB/GYNs) in Japan, the Japanese Society of Obstetrics and Gynecology (JSOG) conducted a national-wide survey. An email survey was sent to all JSOG members (16 732) and a web-based survey was conducted using a Google form between September and November 2021. The current status and problems in PMS/PMDD diagnosis and treatment were surveyed in this cross-sectional study. In total, 1312 respondents (7.8% of all JSOG members) completed the questionnaire. In terms of diagnoses and treatment, OB/GYN was preferred over psychiatrist for PMS (91.4% vs. 45%); however, no differences were noted for PMDD (76.1% vs. 73.7%). A total of 1267 (96.6%) respondents engaged in routine PMS/PMDD treatment. Regarding the general diagnosis procedure, 84.4% respondents answered "only a vague medical interview," 8.4% kept a two-cycle symptom diary, and 10.3% used a screening questionnaire. The most commonly used medication was oral contraceptive pills (OCPs) (98.1%), followed by the Kampo, traditional Japanese herbal medicines, Kamishoyosan (73.6%). Concerning first-line drugs for treatment, OCPs were the most common (76.8%), followed by Kampo medicine (19.5%); selective serotonin reuptake inhibitors (SSRIs) were less frequently used (2.6%). Regarding first-line drugs among OCPs, 65.1% respondents reported drospirenone-ethinylestradriol use. This study indicates that only a few OB/GYNs practicing PMS/PMDD in Japan use a prospective diary, which is an essential diagnostic criterion for PMS/PMDD. Regarding treatment, SSRIs were used less frequently.
Substances chimiques
Selective Serotonin Reuptake Inhibitors
0
Contraceptives, Oral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1375-1382Informations de copyright
© 2023 The Authors. Journal of Obstetrics and Gynaecology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Obstetrics and Gynecology.
Références
Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol. 2018;218(1):68-74.
Angst J, Sellaro R, Merikangas KR, Endicott J. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand. 2001;104(2):110-6.
Pearlstein T, Steiner M. Premenstrual dysphoric disorder: burden of illness and treatment update. J Psychiatry Neurosci. 2008;33(4):291-301.
O'Brien PM, Backstrom T, Brown C, Dennerstein L, Endicott J, Epperson CN, et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Womens Ment Health. 2011;14(1):13-21.
Rubinow DR, Roy-Byrne P. Premenstrual syndromes: overview from a methodologic perspective. Am J Psychiatry. 1984;141(2):163-72.
Henz A, Ferreira CF, Oderich CL, Gallon CW, Castro JRS, Conzatti M, et al. Premenstrual syndrome diagnosis: a comparative study between the Daily Record of Severity of Problems (DRSP) and the Premenstrual Symptoms Screening Tool (PSST). Rev Bras Ginecol Obstet. 2018;40(1):20-5.
ACOG practice bulletin. Int J Gynecol Obstet. 2001;73(2):183-91.
Association AP. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, D.C.: American Psychiatric Association; 2013.
Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health. 2006;9(1):41-9.
Management of premenstrual syndrome: Green-top guideline no. 48. BJOG. 2017;124(3):e73-e105.
Craner JR, Sigmon ST, McGillicuddy ML. Does a disconnect occur between research and practice for Premenstrual Dysphoric Disorder (PMDD) diagnostic procedures? Women Health. 2014;54(3):232-44.
Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Womens Ment Health. 2003;6(3):203-9.
Miyaoka Y, Akimoto Y, Ueda K, Ujiie Y, Kametani M, Uchiide Y, et al. Fulfillment of the premenstrual dysphoric disorder criteria confirmed using a self-rating questionnaire among Japanese women with depressive disorders. Biopsychosoc Med. 2011;5:5.
Takeda T, Tasaka K, Sakata M, Murata Y. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in Japanese women. Arch Womens Ment Health. 2006;9(4):209-12.
Takeda T, Yoshimi K, Yamada K. Psychometric testing of the premenstrual symptoms questionnaire and the association between perceived injustice and premenstrual symptoms: a cross-sectional study among Japanese high school students. Int J Womens Health. 2020;12:755-63.
Kawaguchi R, Matsumoto K, Akira S, Ishitani K, Iwasaku K, Ueda Y, et al. Guidelines for office gynecology in Japan: Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2017 edition. J Obstet Gynaecol Res. 2019;45(4):766-86.
The United Nations. World contraceptive use 2022. 2022.
Ando S, Yamaguchi S, Aoki Y, Thornicroft G. Review of mental-health-related stigma in Japan. Psychiatry Clin Neurosci. 2013;67(7):471-82.
Zhang Z, Sun K, Jatchavala C, Koh J, Chia Y, Bose J, et al. Overview of stigma against psychiatric illnesses and advancements of anti-stigma activities in six Asian societies. Int J Environ Res Public Health. 2019;17(1):280.
Luft MJ, Lamy M, DelBello MP, McNamara RK, Strawn JR. Antidepressant-induced activation in children and adolescents: risk, recognition and management. Curr Probl Pediatr Adolesc Health Care. 2018;48(2):50-62.
Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ. 2005;330(7488):396.
Cohen LS, Soares CN, Lyster A, Cassano P, Brandes M, Leblanc GA. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol. 2004;24(5):540-3.
Singh D, Saadabadi A, editors. Venlafaxine. StatPearls. Treasure Island, FL: StatPearls Publishing; 2022.
Hofmeister S, Bodden S. Premenstrual syndrome and premenstrual dysphoric disorder. Am Fam Physician. 2016;94(3):236-40.
Cohen J. A power primer. Psychol Bull. 1992;112(1):155-9.
Tanaka E, Momoeda M, Osuga Y, Rossi B, Nomoto K, Hayakawa M, et al. Burden of menstrual symptoms in Japanese women: results from a survey-based study. J Med Econ. 2013;16(11):1255-66.
Yoshida H, Sakamoto H, Leslie A, Takahashi O, Tsuboi S, Kitamura K. Contraception in Japan: current trends. Contraception. 2016;93(6):475-7.
Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2012;(2):Cd006586.
Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005;72(6):414-21.
Marr J, Heinemann K, Kunz M, Rapkin A. Ethinyl estradiol 20μg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. Int J Gynaecol Obstet. 2011;113(2):103-7.
Ismaili E, Walsh S, O'Brien PMS, Bäckström T, Brown C, Dennerstein L, et al. Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder. Arch Womens Ment Health. 2016;19(6):953-8.
Takeda T, Yamaguchi T, Yaegashi N. Perceptions and attitudes of Japanese gynecologic cancer patients to Kampo (Japanese herbal) medicines. Int J Clin Oncol. 2012;17(2):143-9.
Suzuki N. Complementary and alternative medicine: a Japanese perspective. Evid Based Complement Alternat Med. 2004;1:113-8.
Shimizu S, Ishino Y, Takeda T, Tohyama M, Miyata S. Antidepressive effects of Kamishoyosan through 5-HT1AReceptor and PKA-CREB-BDNF signaling in the hippocampus in postmenopausal depression-model mice. Evid Based Complement Alternat Med. 2019;2019:9475384.